Shares of Johnson & Johnson (JNJ) were down 1.1% in trading on Wednesday after the company said it had halted late-stage clinical trials for pimodivir, which it was testing as a treatment for people with influenza A. J&J said interim analyses from a Phase 3 trial indicated that the investigational therapy when combined with the standard of care was unlikely to have an added benefit for patients hospitalized with the virus. It halted two trials, one testing pimodivir in outpatients and the other for hospitalized patients. The pimodivir program previously received funding from the Biomedical Advanced Research and Development Authority. J&J's stock is up 3.1% so far this year, while the S&P 500 has gained 9.2%.
-Jaimy Lee; 415-439-6400; AskNewswires@dowjones.com
(END) Dow Jones Newswires
September 02, 2020 09:45 ET (13:45 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.